{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T00:23:20Z","timestamp":1719361400355},"reference-count":39,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,6,25]]},"DOI":"10.7759\/cureus.63105","type":"journal-article","created":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T12:37:15Z","timestamp":1719319035000},"source":"Crossref","is-referenced-by-count":0,"title":["Distinguishing Physiological Ureter Uptake From an Involved Lymph Node in Staging Prostate-Specific Membrane Antigen (PSMA) Scans: Implications for Radiation Planning"],"prefix":"10.7759","author":[{"given":"Lauren","family":"Ching","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Bourne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tim","family":"Kearney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karbi","family":"Choudhury","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan L","family":"Zwart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Malika T","family":"Danner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simeng","family":"Suy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Esposito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sean","family":"Collins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel RL","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023, 73:17-48. 10.3322\/caac.21763","journal-title":"CA Cancer J Clin"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2019.02.033","article-title":"Prostate imaging reporting and data system version 2.1: 2019 update of prostate imaging reporting and data system version 2","volume":"76","author":"Turkbey B","year":"2019","unstructured":"Turkbey B, Rosenkrantz AB, Haider MA, et al.. Prostate imaging reporting and data system version 2.1: 2019 update of prostate imaging reporting and data system version 2. Eur Urol. 2019, 76:340-51. 10.1016\/j.eururo.2019.02.033","journal-title":"Eur Urol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1053\/j.semnuclmed.2023.07.001","article-title":"PSMA PET\/CT for primary staging of prostate cancer - an updated overview","volume":"54","author":"Jochumsen MR","year":"2024","unstructured":"Jochumsen MR, Bouchelouche K. PSMA PET\/CT for primary staging of prostate cancer - an updated overview. Semin Nucl Med. 2024, 54:39-45. 10.1053\/j.semnuclmed.2023.07.001","journal-title":"Semin Nucl Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.4103\/UA.UA_170_20","article-title":"Traditional and novel imaging modalities for advanced prostate cancer: a critical review","volume":"15","author":"Hill S","year":"2023","unstructured":"Hill S, Kassam F, Verma S, Sidana A. Traditional and novel imaging modalities for advanced prostate cancer: a critical review. Urol Ann. 2023, 15:249-55. 10.4103\/UA.UA_170_20","journal-title":"Urol Ann"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2022.101438","article-title":"PSMA theragnostics for metastatic castration resistant prostate cancer","volume":"22","author":"Song H","year":"2022","unstructured":"Song H, Guja KE, Iagaru A. PSMA theragnostics for metastatic castration resistant prostate cancer. Transl Oncol. 2022, 22:10.1016\/j.tranon.2022.101438","journal-title":"Transl Oncol"},{"key":"ref6","unstructured":"FDA approves second PSMA-targeted PET imaging drug for men with prostate cancer. (2021). https.\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fda-approves-second-psma-targeted-pet-imaging-drug-men-prostate-cancer."},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000001698","article-title":"A phase 2\/3 prospective multicenter study of the diagnostic accuracy of prostate specific membrane antigen PET\/CT with (18)F-DCFPyL in prostate cancer patients (OSPREY)","volume":"206","author":"Pienta KJ","year":"2021","unstructured":"Pienta KJ, Gorin MA, Rowe SP, et al.. A phase 2\/3 prospective multicenter study of the diagnostic accuracy of prostate specific membrane antigen PET\/CT with (18)F-DCFPyL in prostate cancer patients (OSPREY). J Urol. 2021, 206:52-61. 10.1097\/JU.0000000000001698","journal-title":"J Urol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-4573","article-title":"Diagnostic performance of (18)F-DCFPyL-PET\/CT in men with biochemically recurrent prostate cancer: results from the CONDOR phase III, multicenter study","volume":"27","author":"Morris MJ","year":"2021","unstructured":"Morris MJ, Rowe SP, Gorin MA, et al.. Diagnostic performance of (18)F-DCFPyL-PET\/CT in men with biochemically recurrent prostate cancer: results from the CONDOR phase III, multicenter study. Clin Cancer Res. 2021, 27:3674-82. 10.1158\/1078-0432.CCR-20-4573","journal-title":"Clin Cancer Res"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15030796","article-title":"Prostate cancer-PET imaging update","volume":"15","author":"Jetty S","year":"2023","unstructured":"Jetty S, Loftus JR, Patel A, Gupta A, Puri S, Dogra V. Prostate cancer-PET imaging update. Cancers (Basel). 2023, 15:10.3390\/cancers15030796","journal-title":"Cancers (Basel)"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1002\/pros.23347","article-title":"(68) Ga-PSMA-PET for radiation treatment planning in prostate cancer recurrences after surgery: individualized medicine or new standard in salvage treatment","volume":"77","author":"Habl G","year":"2017","unstructured":"Habl G, Sauter K, Schiller K, Dewes S, Maurer T, Eiber M, Combs SE. (68) Ga-PSMA-PET for radiation treatment planning in prostate cancer recurrences after surgery: individualized medicine or new standard in salvage treatment. Prostate. 2017, 77:920-7. 10.1002\/pros.23347","journal-title":"Prostate"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-008-1174-8","article-title":"Endorectal magnetic resonance imaging at 1.5 Tesla to assess local recurrence following radical prostatectomy using T2-weighted and contrast-enhanced imaging","volume":"19","author":"Cirillo S","year":"2009","unstructured":"Cirillo S, Petracchini M, Scotti L, et al.. Endorectal magnetic resonance imaging at 1.5 Tesla to assess local recurrence following radical prostatectomy using T2-weighted and contrast-enhanced imaging. Eur Radiol. 2009, 19:761-9. 10.1007\/s00330-008-1174-8","journal-title":"Eur Radiol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1148\/rg.2019180079","article-title":"Revisiting prostate cancer recurrence with PSMA PET: atlas of typical and atypical patterns of spread","volume":"39","author":"Barbosa FG","year":"2019","unstructured":"Barbosa FG, Queiroz MA, Nunes RF, Viana PC, Marin JF, Cerri GG, Buchpiguel CA. Revisiting prostate cancer recurrence with PSMA PET: atlas of typical and atypical patterns of spread. Radiographics. 2019, 39:186-212. 10.1148\/rg.2019180079","journal-title":"Radiographics"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1240939","article-title":"Intensity modulated radiation therapy with stereotactic body radiation therapy boost for unfavorable prostate cancer: five-year outcomes","volume":"13","author":"Carrasquilla M","year":"2023","unstructured":"Carrasquilla M, Sholklapper T, Pepin AN, et al.. Intensity modulated radiation therapy with stereotactic body radiation therapy boost for unfavorable prostate cancer: five-year outcomes. Front Oncol. 2023, 13:10.3389\/fonc.2023.1240939","journal-title":"Front Oncol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.607698","article-title":"Utilization of iodinated SpaceOAR Vue during robotic prostate stereotactic body radiation therapy (SBRT) to identify the rectal-prostate interface and spare the rectum: a case report","volume":"10","author":"Conroy D","year":"2020","unstructured":"Conroy D, Becht K, Forsthoefel M, et al.. Utilization of iodinated SpaceOAR Vue during robotic prostate stereotactic body radiation therapy (SBRT) to identify the rectal-prostate interface and spare the rectum: a case report. Front Oncol. 2020, 10:10.3389\/fonc.2020.607698","journal-title":"Front Oncol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctro.2018.10.006","article-title":"Ano-rectal wall dose-surface maps localize the dosimetric benefit of hydrogel rectum spacers in prostate cancer radiotherapy","volume":"14","author":"Vanneste BG","year":"2019","unstructured":"Vanneste BG, Buettner F, Pinkawa M, Lambin P, Hoffmann AL. Ano-rectal wall dose-surface maps localize the dosimetric benefit of hydrogel rectum spacers in prostate cancer radiotherapy. Clin Transl Radiat Oncol. 2019, 14:17-24. 10.1016\/j.ctro.2018.10.006","journal-title":"Clin Transl Radiat Oncol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1186\/1748-717X-8-58","article-title":"Stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer: the Georgetown University experience","volume":"8","author":"Chen LN","year":"2013","unstructured":"Chen LN, Suy S, Uhm S, et al.. Stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer: the Georgetown University experience. Radiat Oncol. 2013, 8:10.1186\/1748-717X-8-58","journal-title":"Radiat Oncol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1289249","article-title":"Early biochemical outcomes following neoadjuvant\/adjuvant relugolix with stereotactic body radiation therapy for intermediate to high risk prostate cancer","volume":"13","author":"Gallagher L","year":"2023","unstructured":"Gallagher L, Xiao J, Hsueh J, et al.. Early biochemical outcomes following neoadjuvant\/adjuvant relugolix with stereotactic body radiation therapy for intermediate to high risk prostate cancer. Front Oncol. 2023, 13:10.3389\/fonc.2023.1289249","journal-title":"Front Oncol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1186\/s40644-017-0133-5","article-title":"(68)Ga PSMA-11 PET with CT urography protocol in the initial staging and biochemical relapse of prostate cancer","volume":"17","author":"Iravani A","year":"2017","unstructured":"Iravani A, Hofman MS, Mulcahy T, Williams S, Murphy D, Parameswaran BK, Hicks RJ. (68)Ga PSMA-11 PET with CT urography protocol in the initial staging and biochemical relapse of prostate cancer. Cancer Imaging. 2017, 17:10.1186\/s40644-017-0133-5","journal-title":"Cancer Imaging"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics11071191","article-title":"Comparison of early imaging and imaging 60 min post-injection after forced diuresis with furosemide in the assessment of local recurrence in prostate cancer patients with biochemical recurrence referred for 68Ga-PSMA-11 PET\/CT","volume":"11","author":"Bayerschmidt S","year":"2021","unstructured":"Bayerschmidt S, Uprimny C, Kroiss AS, et al.. Comparison of early imaging and imaging 60 min post-injection after forced diuresis with furosemide in the assessment of local recurrence in prostate cancer patients with biochemical recurrence referred for 68Ga-PSMA-11 PET\/CT. Diagnostics (Basel). 2021, 11:10.3390\/diagnostics11071191","journal-title":"Diagnostics (Basel)"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1097\/COC.0000000000000010","article-title":"Low toxicity in inflammatory bowel disease patients treated with abdominal and pelvic radiation therapy","volume":"38","author":"White EC","year":"2015","unstructured":"White EC, Murphy JD, Chang DT, Koong AC. Low toxicity in inflammatory bowel disease patients treated with abdominal and pelvic radiation therapy. Am J Clin Oncol. 2015, 38:564-9. 10.1097\/COC.0000000000000010","journal-title":"Am J Clin Oncol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/s0360-3016(01)01629-7","article-title":"Acute and late radiotherapy toxicity in patients with inflammatory bowel disease","volume":"51","author":"Song DY","year":"2001","unstructured":"Song DY, Lawrie WT, Abrams RA, Kafonek DR, Bayless TM, Welsh JS, DeWeese TL. Acute and late radiotherapy toxicity in patients with inflammatory bowel disease. Int J Radiat Oncol Biol Phys. 2001, 51:455-9. 10.1016\/s0360-3016(01)01629-7","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1186\/s13014-021-01850-1","article-title":"Stereotactic body radiation therapy for the treatment of localized prostate cancer in men with underlying inflammatory bowel disease","volume":"16","author":"Lischalk JW","year":"2021","unstructured":"Lischalk JW, Blacksburg S, Mendez C, et al.. Stereotactic body radiation therapy for the treatment of localized prostate cancer in men with underlying inflammatory bowel disease. Radiat Oncol. 2021, 16:10.1186\/s13014-021-01850-1","journal-title":"Radiat Oncol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.adro.2021.100759","article-title":"Toxicity after stereotactic body radiation therapy for prostate cancer in patients with inflammatory bowel disease: a multi-institutional matched case-control series","volume":"6","author":"Juarez JE","year":"2021","unstructured":"Juarez JE, Romero T, Mantz CA, et al.. Toxicity after stereotactic body radiation therapy for prostate cancer in patients with inflammatory bowel disease: a multi-institutional matched case-control series. Adv Radiat Oncol. 2021, 6:10.1016\/j.adro.2021.100759","journal-title":"Adv Radiat Oncol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1038\/s41391-019-0177-7","article-title":"The association between inflammatory bowel disease and prostate cancer risk: a meta-analysis","volume":"23","author":"Ge Y","year":"2020","unstructured":"Ge Y, Shi Q, Yao W, Cheng Y, Ma G. The association between inflammatory bowel disease and prostate cancer risk: a meta-analysis. Prostate Cancer Prostatic Dis. 2020, 23:53-8. 10.1038\/s41391-019-0177-7","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.4103\/0972-9941.181324","article-title":"Inflammatory stricture of the right ureter following perforated appendicitis: the first Indian report","volume":"12","author":"Rajkumar JS","year":"2016","unstructured":"Rajkumar JS, Ganesh D, Rajkumar A. Inflammatory stricture of the right ureter following perforated appendicitis: the first Indian report. J Minim Access Surg. 2016, 12:375-7. 10.4103\/0972-9941.181324","journal-title":"J Minim Access Surg"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.3978\/j.issn.2223-4683.2014.04.01","article-title":"Urinary adverse effects of pelvic radiotherapy","volume":"3","author":"Liberman D","year":"2014","unstructured":"Liberman D, Mehus B, Elliott SP. Urinary adverse effects of pelvic radiotherapy. Transl Androl Urol. 2014, 3:186-95. 10.3978\/j.issn.2223-4683.2014.04.01","journal-title":"Transl Androl Urol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1186\/s13550-016-0233-4","article-title":"Impact of (68)Ga-PSMA PET\/CT on salvage radiotherapy planning in patients with prostate cancer and persisting PSA values or biochemical relapse after prostatectomy","volume":"6","author":"Bluemel C","year":"2016","unstructured":"Bluemel C, Linke F, Herrmann K, et al.. Impact of (68)Ga-PSMA PET\/CT on salvage radiotherapy planning in patients with prostate cancer and persisting PSA values or biochemical relapse after prostatectomy. EJNMMI Res. 2016, 6:10.1186\/s13550-016-0233-4","journal-title":"EJNMMI Res"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1080\/0284186X.2023.2259597","article-title":"Patient-reported persistent symptoms after radiotherapy and association with quality of life for prostate cancer survivors","volume":"62","author":"Spampinato S","year":"2023","unstructured":"Spampinato S, Rancati T, Waskiewicz JM, et al.. Patient-reported persistent symptoms after radiotherapy and association with quality of life for prostate cancer survivors. Acta Oncol. 2023, 62:1440-50. 10.1080\/0284186X.2023.2259597","journal-title":"Acta Oncol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/j.prro.2017.11.008","article-title":"Stereotactic body radiation therapy (SBRT) for high-risk prostate cancer: where are we now?","volume":"8","author":"Gonzalez-Motta A","year":"2018","unstructured":"Gonzalez-Motta A, Roach M 3rd. Stereotactic body radiation therapy (SBRT) for high-risk prostate cancer: where are we now?. Pract Radiat Oncol. 2018, 8:185-202. 10.1016\/j.prro.2017.11.008","journal-title":"Pract Radiat Oncol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2023.0050","article-title":"Prostate cancer, version 4.2023, NCCN Clinical Practice Guidelines in Oncology","volume":"21","author":"Schaeffer E","year":"2023","unstructured":"Schaeffer E, Srinivas S, Nabil A, et al.. Prostate cancer, version 4.2023, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Net. 2023, 21:1067-96. 10.6004\/jnccn.2023.0050","journal-title":"J Natl Compr Canc Net"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.120.252114","article-title":"Safety, biodistribution, and radiation dosimetry of (18)F-rhPSMA-7.3 in healthy adult volunteers","volume":"62","author":"Tolvanen T","year":"2021","unstructured":"Tolvanen T, Kalliokoski K, Malaspina S, et al.. Safety, biodistribution, and radiation dosimetry of (18)F-rhPSMA-7.3 in healthy adult volunteers. J Nucl Med. 2021, 62:679-84. 10.2967\/jnumed.120.252114","journal-title":"J Nucl Med"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1967\/s002449912437","article-title":"Comparative study of the most commonly-used radiopharmaceuticals for PSMA prostate PET\/CT imaging","volume":"25","author":"Pasini E","year":"2022","unstructured":"Pasini E, Panagiotidis E, Zoglopitou LA, Kalathas T, Makridou A, Chatzipavlidou V. Comparative study of the most commonly-used radiopharmaceuticals for PSMA prostate PET\/CT imaging. Hell J Nucl Med. 2022, 25:83-7. 10.1967\/s002449912437","journal-title":"Hell J Nucl Med"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2023.06.018","article-title":"Diagnostic performance and safety of positron emission tomography with (18)F-rhPSMA-7.3 in patients with newly diagnosed unfavourable intermediate-to-very-high-risk prostate cancer: results from a phase 3, prospective, multicentre study (LIGHTHOUSE)","volume":"84","author":"Surasi DS","year":"2023","unstructured":"Surasi DS, Eiber M, Maurer T, et al.. Diagnostic performance and safety of positron emission tomography with (18)F-rhPSMA-7.3 in patients with newly diagnosed unfavourable intermediate-to-very-high-risk prostate cancer: results from a phase 3, prospective, multicentre study (LIGHTHOUSE). Eur Urol. 2023, 84:361-70. 10.1016\/j.eururo.2023.06.018","journal-title":"Eur Urol"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.263440","article-title":"Utility of (18)F-rhPSMA-7.3 PET for imaging of primary prostate cancer and preoperative efficacy in N-staging of unfavorable intermediate-to-very high-risk patients validated by histopathology","volume":"63","author":"Langbein T","year":"2022","unstructured":"Langbein T, Wang H, Rauscher I, et al.. Utility of (18)F-rhPSMA-7.3 PET for imaging of primary prostate cancer and preoperative efficacy in N-staging of unfavorable intermediate-to-very high-risk patients validated by histopathology. J Nucl Med. 2022, 63:1334-42. 10.2967\/jnumed.121.263440","journal-title":"J Nucl Med"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.120.260091","article-title":"Detection efficacy of (18)F-rhPSMA-7.3 PET\/CT and impact on patient management in patients with biochemical recurrence of prostate cancer after radical prostatectomy and prior to potential salvage treatment","volume":"62","author":"Rauscher I","year":"2021","unstructured":"Rauscher I, Karimzadeh A, Schiller K, et al.. Detection efficacy of (18)F-rhPSMA-7.3 PET\/CT and impact on patient management in patients with biochemical recurrence of prostate cancer after radical prostatectomy and prior to potential salvage treatment. J Nucl Med. 2021, 62:1719-26. 10.2967\/jnumed.120.260091","journal-title":"J Nucl Med"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000003598","article-title":"Diagnostic performance and safety of (18)F-rhPSMA-7.3 positron emission tomography in men with suspected prostate cancer recurrence: results from a phase 3, prospective, multicenter study (SPOTLIGHT)","volume":"210","author":"Jani AB","year":"2023","unstructured":"Jani AB, Ravizzini GC, Gartrell BA, et al.. Diagnostic performance and safety of (18)F-rhPSMA-7.3 positron emission tomography in men with suspected prostate cancer recurrence: results from a phase 3, prospective, multicenter study (SPOTLIGHT). J Urol. 2023, 210:411-2. 10.1097\/JU.0000000000003598","journal-title":"J Urol"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1007\/s11307-023-01867-w","article-title":"Quantitative and qualitative assessment of urinary activity of 18F-flotufolastat-PET\/CT in patients with prostate cancer: a post hoc analysis of the lighthouse and spotlight studies","volume":"26","author":"Kuo PH","year":"2024","unstructured":"Kuo PH, Hermsen R, Penny R, Postema EJ. Quantitative and qualitative assessment of urinary activity of 18F-flotufolastat-PET\/CT in patients with prostate cancer: a post hoc analysis of the lighthouse and spotlight studies. Mol Imaging Biol. 2024, 26:53-60. 10.1007\/s11307-023-01867-w","journal-title":"Mol Imaging Biol"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-022-06089-w","article-title":"PSMA PET\/CT: joint EANM procedure guideline\/SNMMI procedure standard for prostate cancer imaging 2.0","volume":"50","author":"Fendler WP","year":"2023","unstructured":"Fendler WP, Eiber M, Beheshti M, et al.. PSMA PET\/CT: joint EANM procedure guideline\/SNMMI procedure standard for prostate cancer imaging 2.0. Eur J Nucl Med Mol Imaging. 2023, 50:1466-86. 10.1007\/s00259-022-06089-w","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.120.261866","article-title":"Early injection of furosemide increases detection rate of local recurrence in prostate cancer patients with biochemical recurrence referred for (68)Ga-PSMA-11 PET\/CT","volume":"62","author":"Uprimny C","year":"2021","unstructured":"Uprimny C, Bayerschmidt S, Kroiss AS, et al.. Early injection of furosemide increases detection rate of local recurrence in prostate cancer patients with biochemical recurrence referred for (68)Ga-PSMA-11 PET\/CT. J Nucl Med. 2021, 62:1550-7. 10.2967\/jnumed.120.261866","journal-title":"J Nucl Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/256796-distinguishing-physiological-ureter-uptake-from-an-involved-lymph-node-in-staging-prostate-specific-membrane-antigen-psma-scans-implications-for-radiation-planning","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T12:37:23Z","timestamp":1719319043000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/256796-distinguishing-physiological-ureter-uptake-from-an-involved-lymph-node-in-staging-prostate-specific-membrane-antigen-psma-scans-implications-for-radiation-planning"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,25]]},"references-count":39,"URL":"https:\/\/doi.org\/10.7759\/cureus.63105","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6,25]]}}}